Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Parvovirus B19 Infection in Pregnancy: Clinical Manifestations and Fetus/Newborn Outcome

NCT07338279 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-03-06
Last updated
2026-01-13

Condition(s) studied

Parvovirus B19 InfectionPregnancy

Investigational drug(s) / intervention(s)

Collection of clinical data.

Collection of clinical data.: Observational study

Study summary

The goal of this observational study is to define the rate of intrauterine parvovirus B19 infection and fetal/newborn complications after parvovirus B19 infection of pregnant women. Secondary objectives are risk factors, pregnancy outcomes, long-term sequelae and efficacy of the management interventions.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Pregnant women \>18 years with parvovirus B19 infection and their neonates. Exclusion Criteria: * None

Primary outcome measure(s)

  • Percentage of fetuses/newborns with intrauterine B19V infection. — From diagnosis of parvovirus B19 infection in pregnancy to 24/48 hours of life of the newborn.
  • Percentage of fetuses/newborns with complications due to B19V intrauterine infection. — From diagnosis of parvovirus B19 infection in pregnancy to 24/48 hours of life of the newborn.

Trial sites (5)

FacilityCityRegionStatus
Fondazione IRCCS Policlinico San Matteo Pavia Lombardy Recruiting
ASST degli Spedali Civili di Brescia Brescia Italy Not Yet Recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy Recruiting
ASST Fatebenefratelli Sacco Milan Italy Recruiting
Fondazione IRCCS San Gerardo dei Tintori Monza Italy Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07338279 on ClinicalTrials.gov ↗ ← All trials in Italy